

Non Renounceable pro rata offer – Completion of despatch

10 August 2021, Melbourne: Rhythm Biosciences Limited (ASX: RHY) (Rhythm or the Company) advises that the Prospectus and Application Form for the non-renounceable pro rata offer (Entitlement Offer) announced to ASX on 30 July 2021 has been despatched.

Notifications have also been sent to ineligible foreign shareholders pursuant to ASX Listing Rule 7.7.1(b).

For all enquiries concerning the Offer Document, please contact the Company on +61 3 9614 0600.

Released with the authority of the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

202,245,811 Shares
10,295,000 Options

Australian Registered Office

Level 2, 480 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
Eduardo Vom – Non-Executive Director